SEC Probes Matrixx Following FDA Zicam Warning
In a filing with the SEC on Tuesday, Matrixx said it had received an informal inquiry requesting "certain documents and information" related to the FDA's June 16 warning letter. Matrixx said it would fully cooperate with the SEC.
Matrixx said Wednesday that...
To view the full article, register now.